AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

 FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials  AmpliPhi expects to initiate one of these clinical trials in early 2019  AmpliPhi continues to investigate if […]

AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for […]

AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

PUBLIC COMPANY INFORMATION: “Furthermore, treatment with AB-PA01 was safe and well-tolerated. In this case study, bacteriophage therapy has demonstrated to hold much promise for patients with cystic fibrosis suffering from multidrug resistant pulmonary bacterial infections.” AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today […]

AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

riday, May 18, 2018 6:50 am EDT SAN DIEGO PUBLIC COMPANY INFORMATION: “We are delighted to participate in TID 2018 and to share our product development experience and clinical perspective on the promise of phage therapeutics as a potential treatment for combatting increasing, and potentially life-threatening, antibiotic resistance” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: […]

AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference  Signed collaborative agreements with the U.S. Department of Veterans Affairs and the Westmead Hospital in Sydney  Completed two financings for combined gross proceeds of […]

AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

PUBLIC COMPANY INFORMATION: NYSEAM: APHB “We are pleased and encouraged by the support from the NIAID and its commitment to studying the role of bacteriophage in combating infectious diseases” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will […]

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting

Tuesday, April 3, 2018 6:50 am EDT SAN DIEGO PUBLIC COMPANY INFORMATION: NYSEAM: APHB “Additionally, we were able to stop his cycles of recurrent pseudomonal pneumonia and observed re-establishment of commensal respiratory flora. Based on my experience, phage therapy warrants further clinical investigation and is a promising treatment modality for patients suffering from severe and […]

AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock

CATEGORY: Featured Tuesday, March 20, 2018 8:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered […]

AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

CATEGORY: Featured Monday, March 19, 2018 4:10 pm EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company […]